New hope for tough lymphoma: Three-Drug showdown begins
NCT ID NCT07638722
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether a drug called mosunetuzumab works better alone or combined with either zanubrutinib or polatuzumab vedotin for people with marginal zone lymphoma that has returned or stopped responding to treatment. The study will enroll 138 participants and measure how many achieve complete remission. It aims to find more effective options for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mosunetuzumab, zanubrutinib, polatuzumab vedotin
What this could lead to
If successful, this could point toward better treatment options for people with marginal zone lymphoma that has returned or not responded to prior therapy.
What could go wrong
This is an early phase II trial with only 138 participants, so results may not apply to all patients. The combinations may cause side effects like infusion reactions or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.